✨ Free AI Report
OrisDX Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research OrisDX Inc.
Company Research

OrisDX Inc.: Business Overview, Financials & Competitive Analysis

OrisDX Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage oral cancer diagnostics platform with strong academic pedigree but nascent commercial traction; clinical validation is ahead of reimbursement pathway clarity. OrisDX addresses a genuine unmet clinical need with science-backed technology and accomplished founders, but remains in early stage with minimal commercialization signals. Small team size (5-9 employees), no disclosed.

What is OrisDX Inc.'s industry? OrisDX Inc. (orisdx.com) operates in In-Vitro Diagnostics. AskCyborg classifies OrisDX Inc. under In-Vitro Diagnostics in its company registry.

OrisDX has developed a novel non-invasive salivary diagnostic test utilizing biomarker-based molecular genomic techniques to diagnose oral cavity cancers earlier. Founded from University of Chicago research, the start...

5/ 10Mixed

Cyborg Score thesis

Early-stage oral cancer diagnostics platform with strong academic pedigree but nascent commercial traction; clinical validation...

Read the full analyst-debate transcript →
Industry In-Vitro Diagnostics
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 12, 2026
AI-Verified Research
30+ Page Report

Get the Latest OrisDX Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for OrisDX Inc.

AskCyborg analysts argue the bull and bear cases for OrisDX Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
OrisDX Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

OrisDX Inc. Overview

Pro stress-test →

OrisDX has developed a novel non-invasive salivary diagnostic test utilizing biomarker-based molecular genomic techniques to diagnose oral cavity cancers earlier. Founded from University of Chicago research, the startup addresses a critical clinical gap: currently, no oral cancer salivary diagnostics are endorsed by the American Dental Association, and the standard for detecting head and neck cancer is a biopsy, which often occurs at late stages and is associated with poorer patient outcomes.

Strategic Profile

Pro stress-test →

OrisDX is a seed-stage biotech company with proven scientific pedigree and early validation. The company was formed based on a decade of research in the field of liquid biopsy and cancer genomics at the University of Chicago and Johns Hopkins University by top physicians and scientists. The company received a $250,000 Accelerator Award from the Chicago Biomedical Consortium in October 2025 to advance commercialization of its HPV oral cancer detection platform.

Competitive Landscape

Pro stress-test →

OrisDX operates in diagnostic genomics but in a narrowly-defined vertical (salivary oral cancer detection). Broader competitors include molecular diagnostic platforms such as Guardant Health (liquid biopsy oncology) and GeneDx (genomic diagnostics), though these serve different patient populations and clinical workflows. Head-and-neck cancer diagnostics also rely on traditional biopsy workflows, giving OrisDX potential to disrupt standard-of-care.

Industry Context

OrisDX Inc. operates in In-Vitro Diagnostics.

Key facts

Founded: 2023 or 2024 · Headquarters: Chicago, Illinois, United States · Employees: 5-9 · Revenue: Estimated pre-revenue or early-stage pilot revenue; specific figures not publicly disclosed · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for OrisDX Inc..

  • OrisDX has raised $4.92M to date and secured a $250K non-dilutive grant (October 2025), signaling investor and institutional confidence in the HPV detection technology but underscoring early-stage capital constraints for commercialization.
  • The company operates in an uncontested diagnostic niche: no ADA-endorsed salivary oral cancer test exists, positioning OrisDX as a first-mover if clinical evidence supports adoption in dental and primary care settings.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2025Received $250K Chicago Biomedical Consortium Accelerator Award
  • January 2025Company formation narrative and University of Chicago partnership details publicly disclosed
  • +1 moreTrack every material event for OrisDX Inc. as it happens. Explore monitoring →
Get alerted when OrisDX Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Luminance DiagnosticsEarly cancer detection through salivary biomarkers→DynaLab GenomicsOral cancer screening via saliva-based molecular diagnostics→

Compare OrisDX Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

OrisDX Inc. operates in In-Vitro Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse In-Vitro Diagnostics research →
NEW · MCP server

Ask your AI assistant about OrisDX Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare OrisDX Inc. and its top competitor on Cyborg Score”
“What did OrisDX Inc. do this quarter?”
“Is OrisDX Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does OrisDX Inc. do?+
OrisDX has developed a novel non-invasive salivary diagnostic test utilizing biomarker-based molecular genomic techniques to diagnose oral cavity cancers earlier. Founded from University of Chicago research, the start...
What is OrisDX Inc.'s Cyborg Score?+
OrisDX Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are OrisDX Inc.'s main competitors?+
Named competitors include Luminance Diagnostics, DynaLab Genomics. The full competitive landscape is in the AskCyborg report.
How can I get the full OrisDX Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the OrisDX Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track OrisDX Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More In-Vitro Diagnostics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7DiaSorin S.p.A.7Shenzhen New Industries Biomedical Engineering Co., Ltd.4Biosynex SA